ALNYAlnylam Pharmaceuticals Inc
Earnings Recap
• Reported GAAP EPS of $1.55 up 452.27% YoY • Reported revenue of $1.17B up 96.43% YoY • Alnylam reiterates 2026 financial guidance, projecting combined net product revenues of $4,900 million to $5,300 million and total TTR net product revenues of $4,400 million to $4,700 million.
Bullish
Alnylam achieved record Q1 2026 net product revenues of over $1 billion, driven by strong AMVUTTRA growth. The company is advancing its pipeline with faster enrollment in key trials and expanding strategic collaborations for innovation and patient impact.
Bearish
Alnylam faced decreased collaboration revenues and significantly increased R&D and SG&A expenses. The company also saw a 59% decline in ONPATTRO net product revenues and has long timelines for new drug launches.